vs
Side-by-side financial comparison of BILL Holdings, Inc. (BILL) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
BILL Holdings, Inc. is the larger business by last-quarter revenue ($414.7M vs $339.0M, roughly 1.2× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -0.6%, a 13.8% gap on every dollar of revenue. On growth, BILL Holdings, Inc. posted the faster year-over-year revenue change (14.4% vs -2.7%). BILL Holdings, Inc. produced more free cash flow last quarter ($103.8M vs $87.2M). Over the past eight quarters, BILL Holdings, Inc.'s revenue compounded faster (13.3% CAGR vs 0.4%).
BILL Holdings, Inc. is an American company based in San Jose, California, that provides automated, cloud-based software for financial operations for small businesses in the United States. A white-labeled, end-to-end payments automation platform, Bill.com Connect is offered to financial institutions as part of their single sign-on online business banking ecosystem.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
BILL vs HAE — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $414.7M | $339.0M |
| Net Profit | $-2.6M | $44.7M |
| Gross Margin | 79.8% | 59.7% |
| Operating Margin | -4.4% | 19.9% |
| Net Margin | -0.6% | 13.2% |
| Revenue YoY | 14.4% | -2.7% |
| Net Profit YoY | -107.7% | 19.3% |
| EPS (diluted) | $-0.03 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $414.7M | $339.0M | ||
| Q3 25 | $395.7M | $327.3M | ||
| Q2 25 | $383.3M | $321.4M | ||
| Q1 25 | $358.2M | $330.6M | ||
| Q4 24 | $362.6M | $348.5M | ||
| Q3 24 | $358.4M | $345.5M | ||
| Q2 24 | $343.7M | $336.2M | ||
| Q1 24 | $323.0M | — |
| Q4 25 | $-2.6M | $44.7M | ||
| Q3 25 | $-3.0M | $38.7M | ||
| Q2 25 | $-7.1M | $34.0M | ||
| Q1 25 | $-11.6M | $58.0M | ||
| Q4 24 | $33.5M | $37.5M | ||
| Q3 24 | $8.9M | $33.8M | ||
| Q2 24 | $7.6M | $38.4M | ||
| Q1 24 | $31.8M | — |
| Q4 25 | 79.8% | 59.7% | ||
| Q3 25 | 80.5% | 59.5% | ||
| Q2 25 | 80.8% | 59.8% | ||
| Q1 25 | 81.2% | 58.4% | ||
| Q4 24 | 81.6% | 55.5% | ||
| Q3 24 | 82.0% | 54.2% | ||
| Q2 24 | 81.0% | 52.0% | ||
| Q1 24 | 83.0% | — |
| Q4 25 | -4.4% | 19.9% | ||
| Q3 25 | -5.2% | 17.9% | ||
| Q2 25 | -5.8% | 16.8% | ||
| Q1 25 | -8.1% | 21.6% | ||
| Q4 24 | -6.0% | 16.9% | ||
| Q3 24 | -2.1% | 15.0% | ||
| Q2 24 | -6.5% | 11.8% | ||
| Q1 24 | -8.6% | — |
| Q4 25 | -0.6% | 13.2% | ||
| Q3 25 | -0.7% | 11.8% | ||
| Q2 25 | -1.8% | 10.6% | ||
| Q1 25 | -3.2% | 17.5% | ||
| Q4 24 | 9.3% | 10.8% | ||
| Q3 24 | 2.5% | 9.8% | ||
| Q2 24 | 2.2% | 11.4% | ||
| Q1 24 | 9.8% | — |
| Q4 25 | $-0.03 | $0.95 | ||
| Q3 25 | $-0.03 | $0.81 | ||
| Q2 25 | $0.02 | $0.70 | ||
| Q1 25 | $-0.11 | $1.17 | ||
| Q4 24 | $-0.06 | $0.74 | ||
| Q3 24 | $0.08 | $0.66 | ||
| Q2 24 | $0.37 | $0.74 | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $363.4M |
| Total DebtLower is stronger | $1.8B | $1.2B |
| Stockholders' EquityBook value | $3.8B | $911.5M |
| Total Assets | $10.1B | $2.5B |
| Debt / EquityLower = less leverage | 0.48× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $363.4M | ||
| Q3 25 | $1.1B | $296.4M | ||
| Q2 25 | $1.0B | $292.9M | ||
| Q1 25 | $1.0B | $306.8M | ||
| Q4 24 | $1.6B | $320.8M | ||
| Q3 24 | $853.5M | $299.3M | ||
| Q2 24 | $985.9M | $344.4M | ||
| Q1 24 | $952.5M | — |
| Q4 25 | $1.8B | $1.2B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $914.8M | — | ||
| Q2 24 | $914.0M | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $3.8B | $911.5M | ||
| Q3 25 | $3.9B | $849.2M | ||
| Q2 25 | $3.9B | $882.3M | ||
| Q1 25 | $3.9B | $820.8M | ||
| Q4 24 | $3.8B | $906.9M | ||
| Q3 24 | $4.0B | $878.9M | ||
| Q2 24 | $4.1B | $905.4M | ||
| Q1 24 | $4.1B | — |
| Q4 25 | $10.1B | $2.5B | ||
| Q3 25 | $10.2B | $2.4B | ||
| Q2 25 | $10.1B | $2.5B | ||
| Q1 25 | $9.6B | $2.5B | ||
| Q4 24 | $9.7B | $2.5B | ||
| Q3 24 | $9.0B | $2.5B | ||
| Q2 24 | $9.2B | $2.5B | ||
| Q1 24 | $9.1B | — |
| Q4 25 | 0.48× | 1.34× | ||
| Q3 25 | 0.48× | 1.44× | ||
| Q2 25 | 0.44× | 1.39× | ||
| Q1 25 | 0.43× | 1.49× | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $105.3M | $93.6M |
| Free Cash FlowOCF − Capex | $103.8M | $87.2M |
| FCF MarginFCF / Revenue | 25.0% | 25.7% |
| Capex IntensityCapex / Revenue | 0.4% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $378.8M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.3M | $93.6M | ||
| Q3 25 | $96.9M | $111.3M | ||
| Q2 25 | $83.8M | $17.4M | ||
| Q1 25 | $99.5M | $116.6M | ||
| Q4 24 | $78.7M | $43.8M | ||
| Q3 24 | $88.6M | $48.8M | ||
| Q2 24 | $78.6M | $-27.4M | ||
| Q1 24 | $66.8M | — |
| Q4 25 | $103.8M | $87.2M | ||
| Q3 25 | $95.6M | $106.3M | ||
| Q2 25 | $81.0M | $13.6M | ||
| Q1 25 | $98.4M | $100.9M | ||
| Q4 24 | $78.3M | $35.2M | ||
| Q3 24 | $88.6M | $39.4M | ||
| Q2 24 | $78.4M | $-33.1M | ||
| Q1 24 | $66.8M | — |
| Q4 25 | 25.0% | 25.7% | ||
| Q3 25 | 24.1% | 32.5% | ||
| Q2 25 | 21.1% | 4.2% | ||
| Q1 25 | 27.5% | 30.5% | ||
| Q4 24 | 21.6% | 10.1% | ||
| Q3 24 | 24.7% | 11.4% | ||
| Q2 24 | 22.8% | -9.8% | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 0.4% | 1.9% | ||
| Q3 25 | 0.3% | 1.5% | ||
| Q2 25 | 0.7% | 1.2% | ||
| Q1 25 | 0.3% | 4.7% | ||
| Q4 24 | 0.1% | 2.5% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 0.1% | 1.7% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | 2.35× | 1.17× | ||
| Q3 24 | 9.94× | 1.44× | ||
| Q2 24 | 10.35× | -0.71× | ||
| Q1 24 | 2.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BILL
| Accounts Payable And Accounts Receivable Solutions | $185.9M | 45% |
| Spend And Expense Interchange Revenue | $166.5M | 40% |
| Interest On Funds Held For Customers | $39.5M | 10% |
| Embedded And Other Solutions | $22.8M | 5% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
